IN2014DN09359A - - Google Patents

Info

Publication number
IN2014DN09359A
IN2014DN09359A IN9359DEN2014A IN2014DN09359A IN 2014DN09359 A IN2014DN09359 A IN 2014DN09359A IN 9359DEN2014 A IN9359DEN2014 A IN 9359DEN2014A IN 2014DN09359 A IN2014DN09359 A IN 2014DN09359A
Authority
IN
India
Prior art keywords
opioid
methods
well
pharmaceutical composition
phosphatidylcholine
Prior art date
Application number
Other languages
English (en)
Inventor
Chun Su Yuan
Chong-Zhi Wang
Maojian Gu
dong-hai Lin
Original Assignee
Univeristy Of Chicago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univeristy Of Chicago filed Critical Univeristy Of Chicago
Publication of IN2014DN09359A publication Critical patent/IN2014DN09359A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IN9359DEN2014 2012-05-04 2013-03-13 IN2014DN09359A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261642837P 2012-05-04 2012-05-04
PCT/US2013/031078 WO2013165577A1 (fr) 2012-05-04 2013-03-13 Augmentations de la biodisponibilité de méthylnaltrexone orale par une formulation à base de phosphatidylcholine

Publications (1)

Publication Number Publication Date
IN2014DN09359A true IN2014DN09359A (fr) 2015-07-17

Family

ID=49514721

Family Applications (1)

Application Number Title Priority Date Filing Date
IN9359DEN2014 IN2014DN09359A (fr) 2012-05-04 2013-03-13

Country Status (13)

Country Link
US (1) US20150190523A1 (fr)
EP (1) EP2854537A4 (fr)
JP (1) JP2015515982A (fr)
KR (1) KR20150006877A (fr)
CN (1) CN104470361A (fr)
AU (1) AU2013257211A1 (fr)
BR (1) BR112014027496A2 (fr)
CA (1) CA2872400A1 (fr)
HK (1) HK1207940A1 (fr)
IL (1) IL235390A0 (fr)
IN (1) IN2014DN09359A (fr)
MX (1) MX2014013425A (fr)
WO (1) WO2013165577A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3206491B1 (fr) * 2014-10-17 2019-11-27 Salix Pharmaceuticals, Inc. Utilisation de méthylnaltrexone pour atténuer une progression de tumeur
WO2021224138A1 (fr) * 2020-05-02 2021-11-11 Bausch Health Ireland Limited Procédés de réduction du risque de mortalité chez des sujets souffrant d'une maladie ou d'une affection sous-jacente par administration de méthylnaltrexone

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7846478B2 (en) * 2002-01-31 2010-12-07 Henkel Ag & Co. Kgaa Bioadhesive composition
CN101432011A (zh) * 2006-02-27 2009-05-13 亚历山大·米哈洛 通过诱导逆适应调节神经递质系统的方法
EP2061440A2 (fr) * 2007-04-04 2009-05-27 Sigmoid Pharma Limited Composition pharmaceutique à base de tacrolimus
EP2306829B1 (fr) * 2008-07-01 2017-01-04 University of Chicago Particules contenant un antagoniste périphérique de récepteur d'opioïde
WO2011083304A1 (fr) * 2010-01-05 2011-07-14 Shire Llc Promédicaments d'opioïdes et leurs utilisations
US20120053130A1 (en) * 2010-08-30 2012-03-01 Bristol-Myers Squibb Company Composition for enhancing absorption of a drug and method

Also Published As

Publication number Publication date
KR20150006877A (ko) 2015-01-19
AU2013257211A1 (en) 2014-11-27
EP2854537A4 (fr) 2016-04-06
IL235390A0 (en) 2014-12-31
CN104470361A (zh) 2015-03-25
HK1207940A1 (en) 2016-02-19
CA2872400A1 (fr) 2013-11-07
MX2014013425A (es) 2015-08-14
WO2013165577A1 (fr) 2013-11-07
EP2854537A1 (fr) 2015-04-08
BR112014027496A2 (pt) 2018-05-15
US20150190523A1 (en) 2015-07-09
JP2015515982A (ja) 2015-06-04

Similar Documents

Publication Publication Date Title
AU2018253544A1 (en) Methods for treating or preventing asthma by administering an IL-4R antagonist
IL233592B (en) The compounds active as p2x4 receptor antagonists and substances containing them for the prevention and treatment of neurogenic pain
WO2012032209A3 (fr) Composition pharmaceutique pour le traitement de l'oeil sec
SG194469A1 (en) Tetrahydroquinoline derivatives useful as bromodomain inhibitors
PH12013501244A1 (en) A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease
IL237318A0 (en) Chemical preparations and methods for increasing the delivery of therapeutic agents through the skin
NZ748451A (en) Methods for treating atopic dermatitis by administering an il-4r antagonist
EP2680899A4 (fr) Dispositifs d'administration de médicament destinés à l'administration d'antagonistes d'opioïde comprenant des formulations pour la naloxone
MX366899B (es) Nuevos compuestos.
DK201270677A (en) Pharmaceutical compositions comprising hydromorphone and naloxone
MX2016004741A (es) Composicion farmaceutica que comprende un antagonista de trpa1 y un agente analgesico.
EP2925340B8 (fr) Compositions pharmaceutiques comprenant des agonistes sélectifs du récepteur de la mélanocortine 1, et leur utilisation dans une méthode thérapeutique
EP2830628A4 (fr) Formes galéniques d'halofuginone et méthodes d'utilisation
MY171526A (en) Pharmaceutical formulation for reducing frequency of urination and method of use thereof
ZA201403927B (en) Spirothienopyran-piperidine derivatives as orl-1 receptor antagonists for their use in the treatment of alcohol dependence and abuse
TR201803744T4 (tr) Skleroderma tedavisinde kullanım için naltrekson içeren bileşimler.
HK1207940A1 (en) Bioavailability of oral methylnaltrexone increases with a phosphatidylcholine-based formulation
PL2611445T3 (pl) Kompozycje buprenorfiny w dużej dawce i ich zastosowanie jako środka przeciwbólowego
EP2738176A4 (fr) Dérivé de camptothécine soluble dans l'eau, composition pharmaceutique à base de ce dérivé et utilisation de celui-ci
PH12014501390A1 (en) Novel therapeutic use of p75 receptor antagonists
MX358211B (es) Una composición farmacéutica de liberación comprendiendo hidroclorotiazida, losartán y basilato de amlodipino.
HK1155907A (en) Particles containing an opioid receptor antagonist and methods of use
IN2013MU02852A (fr)
MX2019009243A (es) Antagonistas il-4r para usarse en el tratamiento o previncion de asma persistente y asma severa.
UA96048C2 (ru) Применение антагониста рецепторов интерлейкина-1 как средства фригопротекторного действия